Abstract
The present investigation aimed to enhance the oral bioavailability of the poorly water-s Glibenclamide (GLB) using amorphous solid dispersions (ASD) with various polymers. The drug-polymer miscibility was predicted using in-silico molecular dynamics simulation, Hansen solubility parameter, Flory-Huggins theory, and Gibb’s free energy calculation. To enhance the solubility further, the effervescence amorphous solid dispersions (ESD) technique was included. The solid dispersions (SDs) were initially prepared using the solvent evaporation method. The polymers that enhanced the solubility were optimized by the Design of Experiments (DoE) approach and Hot Melt Extruder (HME) technique. The optimized formulation were subjected to various solid and liquid state characterizations. The XRD and DSC study confirmed conversion into the amorphous form, and hydrogen bonding between the drug and polymer was confirmed by FTIR and 1H NMR. The morphology was assessed by SEM study. The optimized formulation showed enhanced solubility and dissolution data. The optimized formulation remained stable at the accelerated conditions for six months. The optimized formulation subjected to the pre-clinical pharmacokinetic and pharmacodynamics study showed a better pharmacokinetics profile of the drug and enhanced pharmacological activity. Introducing the effervescent technique to the conventional ASD technique helped to enhance the physicochemical properties with improved pharmacological action.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.